Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Aligos Therapeutics to announce earnings of ($2.44) per share and revenue of $4.85 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.95. The firm had revenue of $27.78 million for the quarter, compared to analyst estimates of $24.68 million. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. On average, analysts expect Aligos Therapeutics to post ($6.81) EPS for the current fiscal year and ($5.39) EPS for the next fiscal year.
Aligos Therapeutics Stock Up 9.1%
Shares of Aligos Therapeutics stock opened at $5.17 on Thursday. The firm has a market capitalization of $32.26 million, a P/E ratio of -0.71 and a beta of 2.36. Aligos Therapeutics has a 52 week low of $3.98 and a 52 week high of $13.69. The firm’s 50 day moving average is $5.63 and its two-hundred day moving average is $6.31.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on ALGS
Aligos Therapeutics Company Profile
Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.
Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.
Featured Stories
- Five stocks we like better than Aligos Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
